Belite Bio Inc ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $29.9001
- Today's High:
- $32.015
- Open Price:
- $30.78
- 52W Low:
- $14.22
- 52W High:
- $44.7
- Prev. Close:
- $30.79
- Volume:
- 73271
Company Statistics
- Market Cap.:
- $422.01 million
- Book Value:
- 1.412
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -25.59%
- Return on Equity TTM:
- -71.21%
Company Profile
Belite Bio Inc ADR had its IPO on 2022-04-29 under the ticker symbol BLTE.
The company operates in the Healthcare sector and Biotechnology industry. Belite Bio Inc ADR has a staff strength of 5 employees.
Stock update
Shares of Belite Bio Inc ADR opened at $30.78 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $29.9 - $32.02, and closed at $30.2.
This is a -1.92% slip from the previous day's closing price.
A total volume of 73,271 shares were traded at the close of the day’s session.
In the last one week, shares of Belite Bio Inc ADR have slipped by -8.48%.
Belite Bio Inc ADR's Key Ratios
Belite Bio Inc ADR has a market cap of $422.01 million, indicating a price to book ratio of 15.4823 and a price to sales ratio of 0.
In the last 12-months Belite Bio Inc ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-18576500. The EBITDA ratio measures Belite Bio Inc ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Belite Bio Inc ADR’s operating margin was 0% while its return on assets stood at -25.59% with a return of equity of -71.21%.
In Q1, Belite Bio Inc ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Belite Bio Inc ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Belite Bio Inc ADR’s profitability.
Belite Bio Inc ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -91.1834. Its price to sales ratio in the trailing 12-months stood at 0.
Belite Bio Inc ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $39.82 million
- Total Liabilities
- $243000.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $18500
- Dividend Payout Ratio
- 0%
Belite Bio Inc ADR ended 2024 with $39.82 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.82 million while shareholder equity stood at $35.17 million.
Belite Bio Inc ADR ended 2024 with $0 in deferred long-term liabilities, $243000.00 in other current liabilities, 250.00 in common stock, $-4389250.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.40 million and cash and short-term investments were $6.40 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Belite Bio Inc ADR’s total current assets stands at $38.42 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $10000.00 compared to accounts payable of $0 and inventory worth $0.
In 2024, Belite Bio Inc ADR's operating cash flow was $0 while its capital expenditure stood at $18500.
Comparatively, Belite Bio Inc ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $30.2
- 52-Week High
- $44.7
- 52-Week Low
- $14.22
- Analyst Target Price
- $57.5
Belite Bio Inc ADR stock is currently trading at $30.2 per share. It touched a 52-week high of $44.7 and a 52-week low of $44.7. Analysts tracking the stock have a 12-month average target price of $57.5.
Its 50-day moving average was $23.43 and 200-day moving average was $26.34 The short ratio stood at 2.69 indicating a short percent outstanding of 0%.
Around 7097.7% of the company’s stock are held by insiders while 358.7% are held by institutions.
Frequently Asked Questions About Belite Bio Inc ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.